FDA Approves Subcutaneous Isatuximab (Sarclisa) for Multiple Myeloma: A New Administration Option

　　1.Drug Overview and Approval Background

　　Isatuximab(generic name:isatuximab-irfc;brand name:Sarclisa)is an anti-CD38 monoclonal antibody developed by Sanofi-Aventis U.S.LLC.On July 9,2026,the U.S.Food and Drug Administration(FDA)approved its subcutaneous injection formulation,offering patients with multiple myeloma(MM)a new route of administration beyond conventional intravenous infusion.

　　Multiple myeloma is a hematologic malignancy originating from clonal plasma cells in the bone marrow.Abnormally proliferating plasma cells produce excessive monoclonal immunoglobulins,progressively damaging bone,kidney,and normal hematopoietic function.Patients commonly present with bone pain,anemia,renal impairment,and recurrent infections,with the disease predominantly affecting older adults.The approval of the subcutaneous formulation represents a significant advancement in treatment convenience.

　　2.FDA-Approved Indications

　　The subcutaneous isatuximab formulation is approved for three distinct adult multiple myeloma populations:

　　First,in combination with pomalidomide and dexamethasone,for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy that included lenalidomide and a proteasome inhibitor.

　　Second,in combination with carfilzomib and dexamethasone,for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.

　　Third,in combination with bortezomib,lenalidomide,and dexamethasone as a quadruplet regimen,for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

　　These indications span the full treatment continuum from newly diagnosed to multi-line refractory disease,reflecting the broad applicability of isatuximab across different stages of myeloma management.

　　3.Pivotal Clinical Trial Data

　　The approval was supported by three key clinical studies,with all efficacy endpoints assessed by an independent review committee(IRC)and the primary endpoint being objective response rate(ORR).

　　The IRAKLIA study(NCT05405166)was a Phase 3,open-label,non-inferiority trial enrolling 531 patients randomized 1:1 to subcutaneous or intravenous isatuximab,both combined with pomalidomide and dexamethasone.The subcutaneous group achieved an ORR of 71.1%versus 70.5%in the intravenous group,confirming non-inferiority.Pharmacokinetic data showed a geometric mean ratio of steady-state trough concentrations(pre-dose on Cycle 6,Day 1)of 1.53,demonstrating stable and adequate drug exposure with subcutaneous administration.

　　The IZALCO study(NCT05704049)was a Phase 2 trial enrolling 74 patients with relapsed or refractory myeloma treated with subcutaneous isatuximab plus carfilzomib and dexamethasone,achieving an ORR of 79.7%.

　　The IsaSocut study(NCT05889221)was a Phase 2 single-arm trial enrolling 74 transplant-ineligible newly diagnosed myeloma patients treated with the quadruplet regimen of subcutaneous isatuximab,bortezomib,lenalidomide,and dexamethasone,achieving an ORR of 97.3%.

　　4.Recommended Dosing

　　The standard dose of subcutaneous isatuximab is 1400 mg per administration via subcutaneous injection.Two delivery methods are available:automated administration using the CirCLIQ on-body delivery device,or manual subcutaneous injection using a syringe with an infusion set.Dosing frequency and treatment duration should be determined according to the specific combination regimen and strictly follow the prescribing information schedule.

　　5.Safety Warnings and Monitoring Requirements

　　The prescribing information highlights several important risk warnings requiring close monitoring:administration-related hypersensitivity and injection-related reactions(which may still occur with subcutaneous delivery),neutropenia,increased risk of infections,second primary malignancies,potential interference with certain laboratory test parameters,and embryo-fetal toxicity.

　　Pregnant women must not use this medication.Women of reproductive potential should employ effective contraception during treatment and for a specified period after discontinuation.Throughout the treatment course,regular monitoring of complete blood counts(with particular attention to neutrophil levels),infection markers,and hepatic and renal function is essential.Adverse reactions should be managed promptly with dose modifications or treatment interruptions based on severity.

　　6.Clinical Utility of the Subcutaneous Formulation

　　Compared with traditional intravenous infusion,the subcutaneous formulation offers multiple practical advantages:significantly reduced in-clinic time per administration,elimination of repeated venous access and associated vascular damage,and improved long-term treatment adherence and patient convenience.Data from all three pivotal studies consistently demonstrate comparable efficacy between subcutaneous and intravenous routes,while the approved indications cover newly diagnosed,relapsed,and multi-line refractory myeloma patients,providing clinicians with a more flexible option for standardized treatment across the disease spectrum.